1Anja Vogt, Ursula Kassner, Ulrike Hostalek, et al. Prolonged - release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study [ J ]. vascular health and risk management ,2007,3 ( 4 ) :467- 479.
2Goldberg A, Alagona PJ, Capuzzi DM, et al. Multiple - dose efficacy and safety of an extended - release form of niacin in the management of hyperlipidemia [ J ]. Am J Cardiol,2000,85 (9) : 1100- 1105.
3Guyton JR, Blazing MA, Hagar J, et al. Extended - release niacin vs. gemfibrozil for the treatment of low levels of high - density lipoprotein cholesterol. Niaspan - Gemfibrozil Study Group [ J ]. Arch Intern Med ,2000,160 ( 8 ) : 1177- 1184.
4Birjmohun RS, Hutten BA, Kastelein JJ,et al. Efficacy and safety of high - density lipoprotein cholesterol - increasing compounds : a meta- analysis of randomized controlled trials[J]. J Am Coil Cardiol, 2005,45(2) :185- 197.
5McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia[ J]. Am J Cardiol,2001,88 ( 3 ) :270- 274.
6Alrasadi K, Awan Z, Alwaili K, et al. Comparison of treatment of severe high - density lipoprotein cholesterol deficiency in men with daily atorvastatin (20mg) versus fenofibrate (200mg) versus extended-release niacin (2g) [J]. Am J Cardiol,2008,102(10): 1341-1347.
7Kashyap ML, Mcgovern ME, Berra K, et al. Long - term safety and efficacy of a once - daily niacin/lovastatin formulation for patients with dyslipidemia [ J ]. Am J Cardiol, 2002,89 ( 6 ) : 672- 678.
8Karas RH,Kashyap ML, Knopp RH, et al. Long -term safety and efficacy of a combination of niacin extended release and simvastatin n patients with dyslipidemia: the OCEANS study[J]. Am J Cardiovase Drugs, 2008,8 ( 2 ) : 69- 81.
9McKenney JM ,Jones PH, Bays HE, et al. Comparative effects on lip d levels of combination therapy with a statin and extended - release niacin or ezetimibe versus a statin alone ( the COMPELL study) [ J ]. Atherosclerosis ,2007,192 ( 2 ) :432- 437.
10Peter Alagona Jr. Beyond LDL cholesterol: the role of eievated triglycerides and low HDL cholesterol in residual CVD risk remaining afer statin therapy[ J]. Am J Manag care. 2009,15 :S65- S73.
